15 Jan 2021
We collaborated with artist Stephanie Fonteyn to celebrate the molecules that have become lifesaving medicines and are helping to accelerate efforts to end malaria for good.
Molecules making a difference
-
As the world continues to fight the COVID-19 pandemic, more than ever, we are reminded of the crucial need to invest in research and development for affordable medicines.
Medicines for Malaria Venture was created at a time when the antimalarial pipeline was virtually empty, and malaria was killing over 1 million people every year. Ever since this time, MMV's scientists, physicians and partners have worked tirelessly to build the largest portfolio of medicines for malaria in history.
-
Coartem® Dispersible
The first high-quality, fixed-dose, artemisinin-based combination therapy tailored to children's needs (co-developed with Novartis). To date, it is estimated to have saved over 840,000 lives.
-
Dihydroartemisinin-piperaquine (Eurartesim®)
Co-developed with Alfasigma, and stringently approved as a treatment for uncomplicated malaria in 2011, today, it is being investigated as a preventive treatment for populations at greater risk of severe infection, like pregnant women.
-
Sulfadoxine-pyrimethamine + amodiaquine (SPAQ)
Every rainy season, SPAQ is deployed as seasonal malaria chemoprevention, protecting over 200 million children in the sub-Sahel region of Africa.
-
Tafenoquine (Kozenis/Krintafel*)
The first-ever single dose treatment to prevent relapse of Plasmodium vivax malaria (co-developed with GSK).
* Trademarks owned by GSK
-
Artesunate injections and artesunate rectocaps
Injectable artesunate has saved an estimated 1 million lives more than quinine would have since 2011, while artesunate rectocaps, a pre-referral intervention, saved 400,000 lives since 2017.
-
Pyronaridine-artesunate (Pyramax®)
The only artemisinin-based combination therapy approved by a stringent regulatory authority to treat both Plasmodium falciparum and Plasmodium vivax malaria (co-developed with Shin Poong).